Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

Max Gelman

Senior Editor

J&J and biotech partner Protagonist Therapeutics claimed a Phase IIb win in plaque psoriasis Tuesday morning. But near-term plans for the drug remain murky. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

De­spite mid-stage plaque pso­ri­a­sis win, J&J ap­pears un­de­cid­ed on PhI­II for part­ner's IL-23 drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug